Association of serum uric acid levels with SYNTAX score II and long term mortality in the patients with stable angina pectoris who undergo percutaneous coronary interventions due to multivessel and/or unprotected left main disease

  • Yavuz KarabağEmail author
  • Ibrahim Rencuzogullari
  • Metin Çağdaş
  • Süleyman Karakoyun
  • Mahmut Yesin
  • Eray Atalay
  • Öznur Sadioglu Çağdaş
  • Mustafa Ozan Gürsoy
  • Cengiz Burak
  • Halil Ibrahim Tanboğa
Original Paper


Serum uric acid (SUA) level was shown in various studies to be related to the presence of coronary artery disease and subsequent cardiovascular events. The aim of the present study was to evaluate the association of SUA with SYNTAX score II (SSII) and the long-term prognosis of patients with stable angina pectoris who underwent percutaneous revascularization due to multivessel disease (MVD) and/or unprotected left main disease (UPLMD). Two-hundred and ninety patients with MVD and/or UPLMD who were treated consecutively with percutaneous coronary intervention (PCI) were included in the present study. The study population was divided into high SSII (n: 145; SSII > 32.9) and low SSII (n: 145; SSII ≤ 32.9) according to the median SSII value. The SUA value was significantly higher in the high SSII group than in the low SSII group (5.53 ± 1.95 vs. 6.07 ± 1.88; p = 0.001) and was found to be an independent predictor of high SSII (OR 1.306; 95% CI 1.119–1.525; p = 0,001). Twenty-eight patients (9.7%) died during the long-term follow-up, and SUA and SSII were additionally found to be independent predictors of long-term mortality (HR 1.245, 95% CI 1.046–1.482, p = 0.014; HR 1.042, 95% CI 1.007–1.079, p = 0.018, respectively). In the present study, SUA level was demonstrated to be associated with high SSII and long-term mortality in patients with MVD and/or UPLMD who were treated with PCI.


Serum uric acid SYNTAX score II Long-term mortality Stable angina pectoris Multivessel disease Unprotected left main disease Percutaneous coronary intervention 



The authors thank for their contributions to the statistical analysis and trial design.

Compliance with ethical standards

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.


  1. 1.
    Kanellis J et al (2003) Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 41(6):1287–1293Google Scholar
  2. 2.
    Johnson RJ et al (2005) A unifying pathway for essential hypertension. Am J Hypertens 18(3):431–440Google Scholar
  3. 3.
    Johnson RJ (2015) Why focus on uric acid? Curr Med Res Opin 31(suppl 2):3–7Google Scholar
  4. 4.
    Libby P. Ridker PM. Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135Google Scholar
  5. 5.
    Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality: the NHANES I epidemiologic follow-up study, 1971–1992. JAMA 283(18):2404–2410Google Scholar
  6. 6.
    Bos MJ et al (2006) Uric acid is a risk factor for myocardial infarction and stroke. Stroke 37(6):1503–1507Google Scholar
  7. 7.
    Zhu Y et al (2015) Serum cystatin C level is associated with carotid intima-media thickening and plaque. Scand J Clin Lab Invest 75(3):265–272Google Scholar
  8. 8.
    Yu J et al (2014) Association between serum uric acid level and the severity of coronary artery disease in patients with obstructive coronary artery disease. Chin Med J 127(6):1039–1045Google Scholar
  9. 9.
    Sianos G et al (2005) The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 1(2):219–227Google Scholar
  10. 10.
    Campos CM et al (2014) Predictive performance of SYNTAX Score II in patients with left main and multivessel coronary artery disease. Circ J 78(8):1942–1949Google Scholar
  11. 11.
    Hayiroglu MI et al (2018) Predictive value of SYNTAX score II for clinical outcomes in cardiogenic shock underwent primary percutaneous coronary intervention; a pilot study. Int J Cardiovasc Imaging 34(3):329–336Google Scholar
  12. 12.
    SYNTAX Score calculator (2016) SYNTAX working-group. Accessed December 2016
  13. 13.
    Farooq V et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 381(9867):639–650Google Scholar
  14. 14.
    Piccolo R et al (2015) Stable coronary artery disease: revascularisation and invasive strategies. Lancet 386(9994):702–713Google Scholar
  15. 15.
    Emond M et al (1994) Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 90(6):2645–2657Google Scholar
  16. 16.
    Min JK et al (2007) Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol 50(12):1161–1170Google Scholar
  17. 17.
    Vranckx P et al (2015) Clinical outcome of patients with stable ischaemic heart disease as compared to those with acute coronary syndromes after percutaneous coronary intervention. EuroIntervention 11(2):171–179Google Scholar
  18. 18.
    Iwakura K et al (2003) Association between hyperglycemia and the no-reflow phenomenon inpatients with acute myocardial infarction. J Am Coll Cardiol 41(1):1–7Google Scholar
  19. 19.
    Hamburger JN et al (1997) Recanalization of total coronary occlusions using a laser guidewire (the European TOTAL Surveillance Study). Am J Cardiol 80(11):1419–1423Google Scholar
  20. 20.
    Ellis SG et al (1990) Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group. Circulation 82(4):1193–1202Google Scholar
  21. 21.
    Gensini GG (1983) A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 51(3):606Google Scholar
  22. 22.
    Leaman DM et al (1981) Coronary artery atherosclerosis. Circulation 63(2):285–292Google Scholar
  23. 23.
    Brkovic V et al (2013) Additive prognostic value of the SYNTAX score over GRACE, TIMI, ZWOLLE, CADILLAC and PAMI risk scores in patients with acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Int J Cardiovasc Imaging 29(6):1215–1228Google Scholar
  24. 24.
    van Gaal WJ et al (2009) The Syntax score predicts peri-procedural myocardial necrosis during percutaneous coronary intervention. Int J Cardiol 135(1):60–65Google Scholar
  25. 25.
    Ishizaka N et al (2007) Higher serum uric acid is associated with increased arterial stiffness in Japanese individuals. Atherosclerosis 192(1):131–137Google Scholar
  26. 26.
    Qureshi AE, Hameed S, Noeman A (2013) Relationship of serum uric acid level and angiographic severity of coronary artery disease in male patients with acute coronary syndrome. Pak J Med Sci 29(5):1137Google Scholar
  27. 27.
    Gur M et al (2008) Relation of serum uric acid levels with the presence and severity of angiographic coronary artery disease. Angiology 59(2):166–171Google Scholar
  28. 28.
    Wheeler JG et al (2005) Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis. PLoS Med 2(3):e76Google Scholar
  29. 29.
    Ekici B et al (2015) The relationship between serum uric acid levels and angiographic severity of coronary heart disease. Kardiologia Polska (Polish Heart J) 73(7):533–538Google Scholar
  30. 30.
    Wang B, Lin L, Zhao C (2016) Related factors of serum uric acid in patients with primary hypertension and hyperhomocysteinemia. Clin Exp Hypertens 38(3):312–316Google Scholar
  31. 31.
    Miyaoka T et al (2014) Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart Vessel 29(4):504–512Google Scholar
  32. 32.
    Kocak ND et al (2016) Serum uric acid levels and uric acid/creatinine ratios in stable chronic obstructive pulmonary disease (COPD) patients: are these parameters efficient predictors of patients at risk for exacerbation and/or severity of disease? Med Sci Monit 22:4169Google Scholar
  33. 33.
    Sotoda Y et al (2017) Association of serum uric acid levels with leg ischemia in patients with peripheral arterial disease after treatment. J Atheroscler Thromb 24:725–734Google Scholar
  34. 34.
    Gonzales GF, Tapia V (2015) Increased levels of serum γ-glutamyltransferase and uric acid on metabolic, hepatic and kidney parameters in subjects at high altitudes. J Basic Clin Physiol Pharmacol 26(1):81–87Google Scholar
  35. 35.
    Yamauchi Y et al (2017) Is serum uric acid independently associated with left ventricular mass index, ejection fraction, and B-type natriuretic peptide among female and male cardiac patients? Int Heart J 58(4):562–569Google Scholar
  36. 36.
    Niskanen LK et al (2004) Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Archives of internal medicine 164(14):1546–1551Google Scholar
  37. 37.
    Liese AD et al (1999) Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. Epidemiology 10:391–397Google Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  • Yavuz Karabağ
    • 1
    Email author
  • Ibrahim Rencuzogullari
    • 1
  • Metin Çağdaş
    • 1
  • Süleyman Karakoyun
    • 1
  • Mahmut Yesin
    • 2
  • Eray Atalay
    • 3
  • Öznur Sadioglu Çağdaş
    • 3
  • Mustafa Ozan Gürsoy
    • 4
  • Cengiz Burak
    • 5
  • Halil Ibrahim Tanboğa
    • 6
  1. 1.Department of CardiologyKafkas University Medical FacultyKarsTurkey
  2. 2.Department of CardiologyKars Harakani State HospitalKarsTurkey
  3. 3.Department of Internal MedicineKafkas University Medical FacultyKarsTurkey
  4. 4.Department of CardiologyGaziemir State HospitalIzmirTurkey
  5. 5.Department of CardiologyMidyat State HospitalMardinTurkey
  6. 6.Department of CardiologyAtaturk University Medical FacultyErzurumTurkey

Personalised recommendations